A citation-based method for searching scientific literature

Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Times Cited: 201



Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh. Diabetes Ther 2014
Times Cited: 52




List of shared articles



Times cited

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
2

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li, Fei Xie. Front Public Health 2021
0

Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Ayodele Odutayo, Bruno R da Costa, Tiago V Pereira, Vinay Garg, Samir Iskander, Fatimah Roble, Rahim Lalji, Cesar A Hincapié, Aquila Akingbade, Myanca Rodrigues,[...]. J Am Heart Assoc 2021
0




Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
48

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
62

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
46

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
24

Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.
Wenying Yang, Linong Ji, Zhiguang Zhou, Valerie A Cain, Kristina M Johnsson, C David Sjöström. J Diabetes 2017
8

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
27

Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
F A Ribola, F B Cançado, J H M Schoueri, V F De Toni, V H R Medeiros, D Feder. Eur Rev Med Pharmacol Sci 2017
25

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).
Andrew McGovern, Michael Feher, Neil Munro, Simon de Lusignan. Diabetes Ther 2017
4


A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
A Avogaro, A Giaccari, P Fioretto, S Genovese, F Purrello, F Giorgino, S Del Prato. Expert Rev Clin Pharmacol 2017
10